Taking a ‘trip’ to improve mental health

A clinical trial involving a psychedelic drug and psychotherapy aims to help patients with hard-to-treat depression and other mental health disorders

A UK neuropharmaceutical company is planning the world’s first clinical trial to treat depression by combining psychotherapy and the mind-expanding psychedelic medicine dimethyltryptamine (DMT). 

DMT is a naturally occurring chemical found in tiny amounts in the human brain and in larger amounts in plants. Chemically similar to the neurotransmitter serotonin (5-HT), it is involved in a variety of physiological functions, including eating, sleep and mood regulation. 

The Small Pharma trial follows on from the drive, led by the world-renowned Imperial College London, to bring psychedelic-assisted therapy out of the fringe into the scientific mainstream. Small Pharma is focused on identifying rapid-acting treatments for depression and other mental health disorders, and is collaborating with Imperial’s Centre for Psychedelic Research.


Dr Robin Carhart-Harris, the centre’s head, says: 

Psychedelic therapy holds a great deal of promise for treating some very serious mental health conditions and may offer new hope to vulnerable people with limited treatment options.


About Small Pharma

We’re a mental health drug development company that’s accelerating the development of fast acting antidepressant treatments using DMT based therapies. We’re dedicated to making a difference.

With a focus on innovative approaches and committed to challenging the status quo, we’re targeting the root causes of depression and hoping to unlock the minds of millions.

Get Small Pharma updates

    Investor Deck

    Follow us: